Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021;19(11):2012-2019.
doi: 10.2174/1570159X19666210225153404.

Interaction between Zinc, GPR39, BDNF and Neuropeptides in Depression

Affiliations
Review

Interaction between Zinc, GPR39, BDNF and Neuropeptides in Depression

Katarzyna Mlyniec. Curr Neuropharmacol. 2021.

Abstract

As one of the most important elements in our body, zinc plays a part in both the pathophysiology of depression and the antidepressant response. Patients suffering from major depression show significantly reduced zinc levels, which are normalized following successful antidepressant treatment. Recent studies have shown the interaction between zinc, GPR39 and neuropeptides, including galanin and neuropeptide Y (NPY). The zinc-sensing receptor GPR39 forms heterotrimers with 5-HT1A and the galanin receptor GalR1 upon their co-expression in mammalian cells. The oligomerization of these heterotrimers is regulated by the zinc concentration, and this may have an influence on depressive-like behavior. The antidepressant-like effect of zinc is linked to elevated levels of brain-derived neurotrophic factor (BDNF) in brain structures associated with emotion, such as the hippocampus and the amygdala. BDNF regulates neuropeptides, including NPY, cholecystokinin (CCK), and substance P or galanin, which are also implicated in mood disorders. This review focuses for the first time on the interaction between zinc, the GPR39 zinc receptor, BDNF and selected neuropeptides in terms of depression in order to determine its possible role in the neuropharmacology of that illness.

Keywords: BDNF; GPR39; GPR39.; antidepressants; depression; neuropeptides; zinc.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
The influence of zinc on CCK release via inhibition of NMDA receptor. Glutamate due to NMDA receptor can modulate the release of cholecystokinin (CCK). In the pathophysiology of depression, both the hihg CCK as well as high glutamate levels are observed (A). Zinc lowers glutamate levels by the inhibion of glutamatergic NMDA receptor and therefore may attenuate CCK realease (B). (A higher resolution/colour version of this figure is available in the electronic copy of the article).
Fig. (2)
Fig. (2)
A possible role of zinc in the oligomerization states among GPR39, GalR1 and 5-HT1A receptors. At high zinc concentrations 5-HT1A-GPR39 heteromer exists as a dominant form. At low zinc concentration the expression of GPR39 decreases and 5-HT1A-GPR39 heteromer is replaced by 5-HT1A-GalR1 heteromer. The oligomer 5-HT1A-GPR39-GalR1 seems to exsist as an intermediate form between 5-HT1A-GPR39 and 5-HT1A-GalR1 heteromers at adequate zinc concentrations. (A higher resolution/colour version of this figure is available in the electronic copy of the article).

Similar articles

Cited by

References

    1. Mlyniec K. Zinc in the glutamatergic theory of depression. Curr. Neuropharmacol. 2015;13(4):505–513. doi: 10.2174/1570159X13666150115220617. - DOI - PMC - PubMed
    1. Młyniec K., Davies C.L., de Agüero Sánchez I.G., Pytka K., Budziszewska B., Nowak G. Essential elements in depression and anxiety. Part I. Pharmacol. Rep. 2014;66(4):534–544. doi: 10.1016/j.pharep.2014.03.001. - DOI - PubMed
    1. Szewczyk B., Poleszak E., Sowa-Kućma M., Wróbel A., Słotwiński S., Listos J., Wlaź P., Cichy A., Siwek A., Dybała M., Gołembiowska K., Pilc A., Nowak G. The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids. 2010;39(1):205–217. doi: 10.1007/s00726-009-0412-y. - DOI - PubMed
    1. Cunha M.P., Machado D.G., Bettio L.E.B., Capra J.C., Rodrigues A.L.S. Interaction of zinc with antidepressants in the tail suspension test. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2008;32(8):1913–1920. doi: 10.1016/j.pnpbp.2008.09.006. - DOI - PubMed
    1. Siwek M., Dudek D., Schlegel-Zawadzka M., Morawska A., Piekoszewski W., Opoka W., Zieba A., Pilc A., Popik P., Nowak G. Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. J. Affect. Disord. 2010;126(3):447–452. doi: 10.1016/j.jad.2010.04.024. - DOI - PubMed